In conclusion, we demonstrated that the p53-armed, oncolytic adenovirus OBP-702 enhances the antitumor efficacy of Ad-p53 DC vaccine therapy in murine CC tumor models by inducing the presentation of p53 peptides bound to MHC molecules on the surface of tumor cells, thereby sensitizing tumor cells to p53-targeting CTLs. The gene discussed is TP53; the disease is neoplasm.